Valuation: Cerus Corporation

Market Cap 63Cr 55Cr 51Cr 47Cr 90Cr 6.04TCr 91Cr 612.67Cr 237.44Cr 2.96TCr 238.12Cr 232.94Cr 10TCr P/E 2026 *
-94.8x
P/E 2027 * -949x
Enterprise Value 63Cr 55Cr 51Cr 47Cr 90Cr 6.04TCr 91Cr 612.67Cr 237.44Cr 2.96TCr 238.12Cr 232.94Cr 10TCr EV / Sales 2026 *
2.66x
EV / Sales 2027 * 2.44x
Free-Float
96.59%
Yield 2026 *
-
Yield 2027 * -
1 day+5.33%
1 week+10.49%
Current month+8.22%
1 month+17.04%
3 months+69.89%
6 months+60.41%
Current year+53.40%
1 week 2.78
Extreme 2.78
3.2
1 month 2.41
Extreme 2.41
3.2
Current year 1.62
Extreme 1.62
3.2
1 year 1.15
Extreme 1.15
3.2
3 years 1.12
Extreme 1.12
3.2
5 years 1.12
Extreme 1.12
8.06
10 years 1.12
Extreme 1.12
8.87
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 82 01/07/2015
Chief Executive Officer 51 01/07/2026
Director of Finance/CFO 54 04/05/2009
Director TitleAgeSince
Chairman 59 16/03/2026
Director/Board Member 72 24/03/2014
Director/Board Member 51 01/07/2026
Date Insider Type Main position Quantity % Market Cap.
09/06Sell

Director

-20,454 0.0102%
02/06Free

Director

60,000 0.0299%
02/06Free

Director

60,000 0.0299%
Change 5-day change 1-year change 3-year change Capi.($)
+5.33%+10.49%+102.56%+28.46% 60Cr
+4.20%+3.30%-16.66%+7.03% 12TCr
+2.92%-1.70%+1.95%-11.16% 1.23TCr
+7.83%+4.05%+43.14%+108.31% 807.62Cr
-0.64%+0.71%-47.91%-71.81% 399.99Cr
+1.85%+3.66%+21.34%+40.15% 257.32Cr
-1.23%+9.52%-10.95%-14.48% 186.26Cr
-0.41%+2.18%-4.28%-25.04% 161.6Cr
-3.31%-9.68%+216.61%+153.84% 157.75Cr
Average +1.84%+5.38%+33.98%+23.92% 1.7TCr
Weighted average by Cap. +3.93%+2.99%-9.10%+10.41%

Financials

2026 *2027 *
Net sales 24Cr 21Cr 19Cr 18Cr 34Cr 2.27TCr 34Cr 230.04Cr 89Cr 1.11TCr 89Cr 87Cr 3.83TCr 26Cr 23Cr 21Cr 19Cr 37Cr 2.47TCr 37Cr 251.03Cr 97Cr 1.21TCr 98Cr 95Cr 4.18TCr
Net income -62.38L -54.5L -50.05L -46.68L -88.49L -59Cr -89.98L -6.03Cr -2.34Cr -29Cr -2.34Cr -2.29Cr -100.36Cr -5L -4L -4L -4L -7L -4.56Cr -7L -46.31L -17.95L -2.24Cr -18L -17.61L -7.71Cr
Net Debt - -
Logo Cerus Corporation
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Employees
268
Date Price Change Volume
02/26/02 $3.160 +5.33% 32,89,829
01/26/01 $3.000 +2.74% 49,09,418
30/26/30 $2.920 -2.34% 21,74,286
29/26/29 $2.990 +2.40% 23,41,268
26/26/26 $2.920 +2.10% 74,34,823
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
3.160USD
Average target price
4.667USD
Spread / Average Target
+47.68%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CERS Stock